Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT05686551
- Locations
- 🇩🇪
Universitätsklinikum Ulm; Klinik für Neurologie, Ulm, Germany
🇺🇸Uab Medicine, Birmingham, Alabama, United States
🇺🇸Barrow Neurological Institute, Phoenix, Arizona, United States
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT05661578
- Locations
- 🇬🇷
University of Athens, Hematological Clinic,; First Department of Propaedeutic Medicine, Athens, Greece
🇺🇸Pikeville Medical Center, Pikeville, Kentucky, United States
🇺🇸Nebraska Methodist Hospital, Omaha, Nebraska, United States
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 400
- Registration Number
- NCT05646862
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇧🇷Instituto D'Or de Pesquisa e Ensino, Rio de Janeiro, RJ, Brazil
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT05645692
- Locations
- 🇦🇺
Lyell McEwin Hospital, Adelaide, South Australia, Australia
🇺🇸University of Alabama At Birmingham, Birmingham, Alabama, United States
🇫🇷Centre Eugène Marquis, Rennes, France
Vamikibart in Participants With Uveitic Macular Edema
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT05642325
- Locations
- 🇬🇧
Gloucestershire Royal Hospital, Gloucester, United Kingdom
🇺🇸Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 225
- Registration Number
- NCT05642312
- Locations
- 🇺🇸
Kaiser Permanente Southern California, Riverside, California, United States
🇺🇸Colorado Retina Associates, PC, Lakewood, Colorado, United States
🇺🇸Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT05634499
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences; Winthrop Rockefeller Cancer Institute, Little Rock, Arkansas, United States
🇺🇸Mount Sinai Medical Center, Miami Beach, Florida, United States
🇺🇸Minnesota Oncology Minneapolis, Minneapolis, Minnesota, United States
Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 56
- Registration Number
- NCT05630066
- Locations
- 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸Rush Medical Center, Chicago, Illinois, United States
🇺🇸Boston Children's Hospital; Department of Neurology, Boston, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT05627557
- Locations
- 🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 168
- Registration Number
- NCT05619744
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States